Biomea Fusion icovamenib abstracts chosen for late-breaking poster presentations at diabetes conference

Biomea Fusion icovamenib abstracts chosen for late-breaking poster presentations at diabetes conference
Biomea Fusion icovamenib research update

Biomea Fusion announced that three abstracts on its investigational therapy icovamenib have been selected for late-breaking poster presentations at the 86th Scientific Sessions of the American Diabetes Association.

The company will present new clinical insights through sessions led by Juan Pablo Frías, M.D., and Mini Balakrishnan, Ph.D. These presentations underscore Biomea Fusion's ongoing development efforts in diabetes research, aiming to highlight novel approaches for disease management and treatment.

Earlier this year, Biomea Fusion visited clinical study sites for Phase II trials of icovamenib in type 2 diabetes, advancing its research efforts according to a previous update. The company is also set to present new icovamenib data for type 1 and type 2 diabetes at the ADA 86th Scientific Sessions in New Orleans as previously announced. Both initiatives highlight Biomea Fusion's continued engagement with leading diabetes research forums.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.